Diselenide-bridged hybrid mesoporous silica for radiosensitization and radioprotection in the radioimmunotherapy of colorectal cancer.

ABSTRACT: Radioimmunotherapy has been recognized as a promising strategy for the treatment of colorectal cancer; however, it faces several challenges, including limited efficacy, weak immune activation, and severe radiation-induced colitis. To address these issues, we developed hollow mesoporous silica nanoparticles (^SeH-MONs) that integrate dynamic diselenide bonds, exhibiting high drug loading ability as well as X-ray-responsive degradation and release properties. The degradation products derived from diselenide bonds differentially modulate selenometabolism in colorectal cancer cells and intestinal epithelial cells, leading to increased reactive oxygen species (ROS) generation in tumor cells while mitigating radiation-induced damage in normal cells. After optimizing the content of dise

SUBMITTER: Zhang F 

PROVIDER: S-EPMC12821053 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature